. 2017 Oct 25;6(8):876–885. doi: 10.1530/EC-17-0293
This work is licensed under a Table 7.
Data extracted from all studies reporting surgical outcomes specifically for the subgroup of non-functional pNETs ≤2 cm.
| n | Inclusion criteria | N1b | M1 | Local recurrence | Metachronous metastases | F/U | 5-year survival | |
|---|---|---|---|---|---|---|---|---|
| Haynes (23) | 39 | Asym | 3 | 92% | ||||
| Bettini (30) | 51 | R0; Asym | 14% | 0 | 3 | 0 | 47 | 94% |
| Lee (19)a | 56 | M0 | 5 (9%) | (0) | 0 | 0 | 52 | 100% |
| Cherefant (13) | 56 | Asym | 4 | 2 | 1 | 33 | 96% | |
| Kuo (14)d | 263 | 6% | 26 | 82% | ||||
| Gratian (24)d | 999 | 65 | 82% | |||||
| Kishi (5)c | 27 | 22% >19 mm |
3 25 mm |
|||||
| Fischer (16) | 61 | 12% | 1 | 31 | 95% | |||
| Birnbaum (17) | 34 | Asym | 3 | |||||
| Jung (26)a | 60 | M0 | (5) | 0 | 0 | 32 | 100% | |
| Sharpe (27)d | 309 | M0 | 60 | 82% | ||||
| Sallinen (18) | 24 | 4 | 1 | 3 | 27 | 88% | ||
| Massironi (6)c | 21 | 9 | 50 | 90% | ||||
| Regenet (7) | 66 | 7 | 34 | 97% | ||||
| Rosenberg (28)a | 8 | M0; G1/2 | 1 | 2 | 34 | |||
| Sadot (29)a | 77 | M0 | 5 | 0 | 57 | 100% | ||
| Zhang (8)c | 61 | 10 mm | 7 | 57 | 83% | |||
| This study | 66 | 13 | 10 | 1 | 1 | 48 | 87% | |
| Totald | 707 | 12.3%b | 30 (9.7%) | 10 (3.1%) | 23 (3.7%) |
aIncluded in the Partelli (2016) systematic review (2); bNodal involvement as reported, allowance is made where reported for low rates of nodal sampling but the total percentage calculated is therefore a lower estimate; cIncludes familial syndromes; dAnalyses of national databases; not included in totals due to unreliable coding.
Asym, asymptomatic presentation; F/U, follow-up; M0, no distant metastases at surgery; R0, uninvolved surgical margin.